Eli Lilly Drug Tirzepatide Meets Weight-loss Goals In Obesity Trial

Eli Lilly Drug Tirzepatide Meets Weight-loss Goals In Obesity Trial

A highly anticipated clinical trial from Eli Lilly showed its Type 2 diabetes drug met its primary endpoints. CNBC’s Meg Tirrell joins ‘Squawk Box’ to break down the results. Watch 2022 Berkshire Hathaway Annual Shareholders Meeting with Warren Buffett and Charlie Munger on Saturday, April 30 at 9:45 a.m. ET https://www.cnbc.com/brklive22/

» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast 
 
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC

https://www.cnbc.com/select/best-credit-cards/ 

#CNBC
#CNBCTV